FDA’s Plaisier: GMP Oversight Must Shift To Outcomes Model
Executive Summary
In an interview with “The Pink Sheet,” the Office of Regulatory Affairs chief says she wants to chart her office’s activities based on their effect on public health instead of simply counting outputs like the number of inspections or 483s.